SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Electra Therapeutics Reports Third Quarter 2026 Financial Results and Recent Portfolio Highlights

Ipsoprubart Advancing in Global Registrational Program as Potential First Treatment for sHLH Broadly; Enrollment Completion Expected in Second Half of 2027Ipsoprubart Therapeutic Expansion Underway in Phase 1 Trial for T/NK Cell Malignancies, with Initial Data Expected in the Second Half of 2027ELA…

ETRA

Related stories